Publicador de contenidos

Investigación, Chagas

ChagasLAMP (GHIT G2020-203)

Field validation of Trypanosoma cruzi-LAMP: a molecular point-of-care test for the control of congenital Chagas disease

A young Bolivian girl is tested for Chagas disease
Foto: Ana Ferreira
Duración
01/04/2021 - 31/03/2023
Coordinador
Julio Alonso
Financiadores
Global Health Innovative Fund (GHIT)

Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, affects ~7 million people, mostly in Latin America. Vector-borne transmission is on the way of being controlled in several countries, but vertical transmission remains an uncontrolled major public-health challenge. Remarkably, available drugs have a very high cure rate in T. cruzi-infected newborns if administered early upon infection, thus a timely diagnose is crucial for treatment success.

However, the algorithm to detect congenital T. cruzi infection involves parasitological methods that lack sensitivity and a serological study must be performed several months later. In many endemic regions, people live far from referral centres which entails that a large proportion of infants rarely go back for diagnosis confirmation and treatment, if infected. Consequently, they evolve to the chronic phase of the disease with the risk of developing severe manifestations.

Molecular-based diagnostics have a very high sensitivity to detect congenital T. cruzi infections, but laboratories in those distant regions are not equipped to perform them. With the aim to provide a suitable point-of-care (POC) test for the timely diagnosis of congenital Chagas disease in these settings, we will validate the implementation of EIKEN T. cruzi loop-mediated isothermal amplification (LAMP) prototype in the field.

Total Funding

¥ 147,127,368

Nuestro equipo

Coordinator

ISGlobal Team

Ver más

Otros proyectos

Ver proyectos pasados

MESA

La Alianza Científica para la Erradicación de la Malaria (MESA) tiene como objetivo avanzar en la ciencia de la erradicación de la malaria.

NHEPACHA

Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas

Estudio inmunológico de la vacuna RTS,S

Estudio de correlatos de protección frente a la malaria después de la vacunación con RTS,S/AS01E: Una evaluación inmunológica exhaustiva en el ensayo clínico de Fase III, doble ciego, aleatorizado, multicéntrico con un grupo control

Euroleish.net

Control of Leishmaniasis. From bench to bedside and community

GREPIMER

Grup de recerca en patología importada i malaties emergents i re-emergents

TESEO

Nuevos regímenes de quimioterapia y biomarcadores para la enfermedad de Chagas

BOHEMIA

Broad One Health Endectocide-based Malaria Intervention in Africa

ASINTMAL

Unravelling Disease Tolerance and Host Resistance in Afebrile 'P. falciparum' Infections: a Prospective Study in Mozambican Adults

ADAM

Administración masiva y focal de fármacos antimaláricos para avanzar hacia la eliminación de la malaria en Mozambique: acelerando la implementación de programas y políticas

MULTIPLY

MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention

Science4Pandemics

Citizens engagement digital platform for collective intelligence in pandemics

HIDDENVIVAX

Novel organ-on-a-chip technology to study extracellular vesicles-mediated cryptic infections in Plasmodium vivax malaria

MENA Migrant Health

Transforming data collection and surveillance to drive migrant health research, care and policy

SexMal

Social affairs and sex in P. falciparum: implications for malaria elimination

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

SMART

Identifying Severe Malaria with a new Aptamer-based Rapid diagnostic Test

MalTransc

Transcriptional regulation of adaptation and developmental decisions in malaria parasites: from epigenetic variation to directed transcriptional responses

GenMoz

P. falciparum genomic intelligence in Mozambique